Eurofins Becomes the Market Leader in Environment Testing Services in Ireland with the Acquisition of ELS and City Analysts
24 February 2018 - 4:00AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a global leader in environment
testing, announces that it has acquired City Analysts Ltd. (“City
Analysts”), a leading provider of accredited water chemistry and
microbiological testing in Ireland.
City Analysts is a centre of excellence for accredited
cryptosporidium analysis and toxicity testing and is unique in
providing mobile laboratory services throughout Ireland. The
company also has expertise in niche areas of water testing,
including aquatic microbiology, toxicology and parasitology. As one
of the few laboratories in Europe with accreditation for aquatic
toxicity testing, City Analysts has strong links with the
pharmaceutical industry in Ireland. The company, which will remain
under the leadership of its management team, will add a specialist
testing facility in Dublin and Clare and 37 employees to Eurofins’
existing workforce in Ireland, as well as a distribution and
collection network, covering all of Ireland.
The City Analysts acquisition is the second transaction
completed by Eurofins Ireland in the past 12 months after the
acquisition of Environmental Laboratory Services (“ELS”) in the
summer of 2017, and highlights Eurofins’ commitment to further grow
its Environment testing global footprint. Following these
acquisitions, Eurofins’ environment testing business has
significantly expanded its service offering and its range of highly
specialist laboratory services in Ireland. Moreover, Eurofins
recently significantly expanded its laboratories and facilities in
Dungarvan, Ireland, allowing the Group to double the volume of
samples tested annually at this site. As a result of all these
recent developments, Eurofins has become the number one environment
testing player in Ireland, offering the most comprehensive
portfolio of state-of-the-art environment testing services in the
region.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are
extremely pleased to welcome City Analysts and ELS to the Eurofins
Group. These acquisitions, together with the expansion of our
Dungarvan facilities, are an example of our commitment to Ireland
and they reinforce Eurofins’ environment testing portfolio and
expand the range of services offered to our clients. The City
Analysts team is an excellent addition to the Eurofins family of
businesses. They share our commitment to quality, customer focus,
team spirit and integrity, ensuring that our customers continue to
benefit from our trusted support but with even more capabilities.
Bringing colleagues from City Analysts together with ELS means we
can extend our range of services and maximise the benefits we can
bring to our Irish clients.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysisEurofins
Scientific through its subsidiaries (hereinafter sometimes
“Eurofins” or “the Group”) believes it is the world leader in food,
environment and pharmaceutical products testing and that it is also
one of the global independent market leaders in certain testing and
laboratory services for agroscience, genomics, discovery
pharmacology and for supporting clinical studies. In addition,
Eurofins is one of the key emerging players in specialty clinical
diagnostic testing in Europe and the USA. With over 30,000 staff in
400 laboratories across 42 countries, Eurofins offers a portfolio
of over 150,000 analytical methods for evaluating the safety,
identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180223005524/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Eurofins Scientific (EU:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Eurofins Scientific (EU:ERF)
Historical Stock Chart
From May 2023 to May 2024